Journal ArticleDOI
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
TLDR
The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.Abstract:
Rheumatoid arthritis (RA) is a progressive polyarthritis that is responsible for over nine million office visits annually. It is likely that most nurse practitioners will care for one or more patients with RA because approximately 1% of the adult population is affected by this disabling disorder. The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.read more
Citations
More filters
Journal ArticleDOI
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal
TL;DR: To compare treatment changes after the rofecoxib withdrawal with changes occurring normally and to re‐assess 12 months afterwards.
Journal ArticleDOI
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years
Jay L. Goldstein,James Aisenberg,Frank L. Lanza,Howard Schwartz,Sands George Harry,Manuela F. Berger,Sharon Pan +6 more
TL;DR: In these healthy older subjects (aged 65-75 years), valdecoxib 20 mg BID was associated with a significantly lower rate of gastroduodenal, gastric, and duodental ulcers than naproxen 500 mg B ID, even after 6.5 days of therapy.
Journal ArticleDOI
Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis
Vivian K. Kawai,Carlos G. Grijalva,Patrick G. Arbogast,Jeffrey R. Curtis,Daniel H. Solomon,Elizabeth Delzell,Lang Chen,Rita Ouellet-Hellstrom,Lisa J. Herrinton,Liyan Liu,Edward F. Mitchel,C. Michael Stein,Marie R. Griffin +12 more
TL;DR: It is hypothesized that initiation of a new disease‐modifying antirheumatic drug (DMARD) for treatment of rheumatoid arthritis would decrease the use of corticosteroids, nonsteroidal antiinflammatory drugs (NSAIDs), and narcotics.
Journal ArticleDOI
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
Richard Nixon,Anthony O'Hagan,Jeremy E. Oakley,Jason Madan,John Stevens,Nick Bansback,Alan Brennan +6 more
TL;DR: The development of a new drug is a major undertaking and it is important to consider carefully the key decisions in the development process, such as the probability of successful drug registration.
Journal ArticleDOI
Diretrizes para o diagnóstico da artrite reumatoide
Licia Maria Henrique da Mota,Bóris Afonso Cruz,Claiton Viegas Brenol,Ivânio Alves Pereira,Lucila Stange Rezende-Fronza,Manoel Barros Bertolo,Max Vitor Carioca Freitas,Nilzio Antônio da Silva,Paulo Louzada-Junior,Rina Dalva Neubarth Giorgio,Rodrigo Aires Corrêa Lima,Ronaldo Adib Kairalla,Alexandre de Melo Kawassaki,Wanderley Marques Bernardo,Geraldo da Rocha Castelar Pinheiro +14 more
References
More filters
Journal ArticleDOI
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
TL;DR: The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA).
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
Related Papers (5)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more